ReviewCA: a cancer journal for clinicians2023
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer.
Review in CA: a cancer journal for clinicians, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Radiotherapy integration after transoral robotic surgery in head and neck cancer: a bibliometric and knowledge-mapping analysis of adjuvant treatment, de-escalation, functional preservation, and survival outcomes.Frontiers in oncology · 2026Pooled it
- Oropharyngeal cancer and human papillomavirus: a visualization based on bibliometric analysis and topic modeling.Frontiers in microbiology · 2024Pooled it
- Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.Nature communications · 2026Trial
- An exploratory study of nimotuzumab combined with toripalimab and chemotherapy for locally advanced tonsillar cancer.Frontiers in immunology · 2026Trial
- Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Trial
- Article
- Plant Bioactive Constituents and Their Potential Benefits in HPV-Positive Oropharyngeal Squamous Cell Carcinoma-A Narrative Review.Current issues in molecular biology · 2026Review
- Induction chemotherapy for locally advanced OPSCC: real-world evidence and HPV-dependent prognostic value of treatment response.Radiation oncology (London, England) · 2026Article
- Deep learning model using contrast-enhanced CT for predicting overall survival in oropharyngeal squamous cell carcinoma: a prospective multicenter study.European radiology · 2026Article
- HPV Detection in Oropharyngeal Cancer: A Narrative Review of Diagnostic and Emerging Molecular Approaches.Diagnostics (Basel, Switzerland) · 2026Review
- Transoral robotic surgery in head and neck cancer: an umbrella review of meta-analyses.International journal of surgery (London, England) · 2026Article
- Article
- Do not try this at home: patterns and outcomes of radiation dose de-escalation in p16-positive oropharyngeal carcinoma.Frontiers in oncology · 2026Article
- Resection margins in transoral oropharyngeal surgery: comparative analysis of robotic and VITOM Eagle-assisted exoscopic approaches.Frontiers in oncology · 2026Article
- [Current application and future development trends of robotic head and neck surgery].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025Review
- The Value of Circulating Tumor HPV DNA in Head and Neck Squamous Cell Cancer: A Review.Diagnostics (Basel, Switzerland) · 2025Review
- HPV associated oropharyngeal cancer in eastern China over the last 7 years: is the incidence in chinese truly exceptionally low?BMC public health · 2025Article
- Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.Oral oncology · 2025Article
- Osteoradionecrosis of the Hyoid Bone: A Systematic Review.Advances in radiation oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Funding
Abstract
The most common cancer caused by human papillomavirus (HPV) infection in the United States is oropharyngeal cancer (OPC), and its incidence has been rising since the turn of the century. Because of substantial long-term morbidities with chemoradiation and the favorable prognosis of HPV-positive OPC, identifying the optimal deintensification strategy for this group has been a keystone of academic head-and-neck surgery, radiation oncology, and medical oncology for over the past decade. However, the first generation of randomized chemotherapy deintensification trials failed to change the standard of care, triggering concern over the feasibility of de-escalation. National database studies estimate that up to one third of patients receive nonstandard de-escalated treatments, which have subspecialty-specific nuances. A synthesis of the multidisciplinary deintensification data and current treatment standards is important for the oncology community to reinforce best practices and ensure optimal patient outcomes. In this review, the authors present a summary and comparison of prospective HPV-positive OPC de-escalation trials. Chemotherapy attenuation compromises outcomes without reducing toxicity. Limited data comparing transoral robotic surgery (TORS) with radiation raise concern over toxicity and outcomes with TORS. There are promising data to support de-escalating adjuvant therapy after TORS, but consensus on treatment indications is needed. Encouraging radiation deintensification strategies have been reported (upfront dose reduction and induction chemotherapy-based patient selection), but level I evidence is years away. Ultimately, stage and HPV status may be insufficient to guide de-escalation. The future of deintensification may lie in incorporating intratreatment response assessments to harness the powers of personalized medicine and integrate real-time surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.